Monograph
A10AE06 - Insulin Degludec |
Not porphyrinogenic |
NP |
Rationale
Insulin degludec has no porphyrinogenic effects.
Chemical description
Antidiabetic pancreatic hormone consisting of polypeptide chains, connected by disulfide bridges.
Metabolism and pharmacokinetics
Insulin degludec is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, which are slowly and continuously absorbed into the bloodstream leading to a flat and stable glucose-lowering-effect.
Degradation of insulin degludec is similar to that of human insulin; all metabolites formed are inactive.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
Muñoz Torres M. Endocrinol Nutr. 2014 Mar;61(3):153-9. |
23890782 |
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Tresiba.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024